These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35348864)

  • 1. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma.
    Youn SY; Kim B; Kim DH; Choi HJ; Sung PS; Choi JI
    Eur Radiol; 2022 Sep; 32(9):6270-6280. PubMed ID: 35348864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 4. LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.
    Wang D; Zhang Y; Lyu R; Jia K; Xu PJ
    Abdom Radiol (NY); 2024 Sep; 49(9):3045-3055. PubMed ID: 38605217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study.
    Lee S; Kim KW; Jeong WK; Jeong SY; Hwang JA; Choi JS; Lee SG; Joh JW
    Ann Surg Oncol; 2021 Oct; 28(11):6782-6789. PubMed ID: 33751296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
    Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
    Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
    Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
    Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study.
    Hwang JA; Lee S; Lee JE; Yoon J; Choi SY; Shin J
    J Magn Reson Imaging; 2023 Mar; 57(3):930-938. PubMed ID: 35833798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
    Wei H; Jiang H; Zheng T; Zhang Z; Yang C; Ye Z; Duan T; Song B
    Eur Radiol; 2021 Apr; 31(4):2289-2302. PubMed ID: 33001306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
    Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
    Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of Liver Imaging Reporting and Data System treatment response algorithm: a systematic review and meta-analysis.
    Youn SY; Kim DH; Choi SH; Kim B; Choi JI; Shin YR; Oh SN; Rha SE
    Eur Radiol; 2021 Jul; 31(7):4785-4793. PubMed ID: 33409795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
    Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
    Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
    Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
    Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: risk scoring system development and validation.
    Park SH; Kim B; Kim S; Park S; Park YH; Shin SK; Sung PS; Choi JI
    Eur Radiol; 2023 May; 33(5):3566-3579. PubMed ID: 36933020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma.
    Bhatti ABH; Hassan M; Rana A; Khan NY; Khan ZA; Zia HH
    J Gastrointest Cancer; 2022 Mar; 53(1):84-90. PubMed ID: 33184772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
    Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
    Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.